Skip to main content
News

Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience

Targeted Therapies for a Silent Struggle

Publications

Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy

Bhatt AP, Pellock SJ, Biernat KA, Walton WG, Wallace BD, Creekmore BC, Letertre MM, Swann JR, Wilson ID, Roques JR, Darr DB, Bailey ST, Montgomery SA, Roach JM, Azcarate-Peril MA, Sartor RB, Gharaibeh RZ, Bultman SJ, Redinbo MR
Proc Natl Acad Sci U S A. 2020 Mar 13. pii: 201918095. doi: 10.1073/pnas.1918095117.
PMID: 32170007 DOI: 10.1073/pnas.1918095117

On Command Drug Delivery via Cell-Conveyed Phototherapeutics
Christina Marvin, Song Ding, Rachel White, Natalia Orlova, Qunzhao Wang, Emilia Zywot, Brianna Vickerman, Lauren Harr, Teresa Tarrant, Paul Dayton, and David Lawrence
Small. 2019 Sep;15(37):e1901442. doi: 10.1002/smll.201901442. Epub 2019 Jul 28.
PMID: 31353802

Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma
Park SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, Cann ML, Johnson GL, Damania B.
Target Oncol. 2019 Aug 19. doi: 10.1007/s11523-019-00662-4. [Epub ahead of print] PMID: 31429028

The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor
Adam D. Pfefferle, David B. Darr, Benjamin C. Calhoun, Kevin R. Mott, Jeffrey M. Rosen, Charles M. Perou
Dis Model Mech. 2019 Jul 5:12(7). pii: dmm037192. doi: 10.1242/dmm.037192.
PMID: 31213486

FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer.
Arceci A, Bonacci T, Wang X, Stewart K, Damrauer JS, Hoadley KA, Emanuele MJ.
Cell Rep. 2019 Mar 12;26(11):3076-3086.e6. doi: 10.1016/j.celrep.2019.02.054.
PMID: 30865895

Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer
Tanioka M, Mott KR, Hollern DP, Fan C, Darr DB, Perou CM,
Genome Med. 2018 Nov 30;10(1):86 doi: 10.1186/s13073-018-0597-3 PMID: 30497520

A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer 
Hollern DP, Contreras CM, Dance-Barnes S, Silva GO, Pfefferle AD, Xiong J, Darr DB, Usary J, Mott KR, Perou CM
Breast Cancer Res. Treat. 2018 Nov 27. doi: 10.1007/s10549-018-5061-y PMID: 30484104

A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1 insensitive models of triple-negative breast cancer 
Cheng N, Watkins-Schulz R, Junkins RD, David CN, Johnson BM, Montgomery SA, Peine KJ, Darr DB, Yuan H, McKinnon KP, Liu Q, Miao L, Huang L, Bachelder EM, Ainslie KM, Ting JP.
JCI Insight. 2018 Nov 15;3(22). pii: 120638. doi: 10.1172/jci.insight.120638. [Epub ahead of print] PMID 30429378

Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy.
Saito R, Smith CC, Utsumi T, Bixby LM, Kardos J, Wobker SE, Stewart KG, Chai S, Manocha U, Byrd KM, Damrauer JS, Williams SE, Vincent BG, Kim WY.
Cancer Res. 2018 Jul 15;78(14):3954-3968. doi: 10.1158/0008-5472.CAN-18-0173. Epub 2018 May 21. PMID:  29784854

Differential response to exercise in claudin-low breast cancer.
Glass OK, Bowie M, Fuller J, Darr D, Usary J, Boss K, Choudhury KR, Liu X, Zhang Z, Locasale JW, Williams C, Dewhirst MW, Jones LW, Seewaldt V.
Oncotarget. 2017 Sep 19;8(60):100989-101004. doi: 10.18632/oncotarget.21054. eCollection 2017 Nov 24. PMID:  29254140

New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.
Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr DB, Karagoz K, Sciaky N, Gatza ML, Sharpless NE, Johnson GL, Bear JE.
Cancer Res. 2018 Jan 15;78(2):542-557. doi: 10.1158/0008-5472.CAN-17-1653. Epub 2017 Nov 27. PMID:  29180473

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.
Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.
Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021. PMID:  29141225

Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling.
Cousins EM, Goldfarb D, Yan F, Roques J, Darr D, Johnson GL, Major MB.
Mol Cancer Res. 2018 Feb;16(2):333-344. doi: 10.1158/1541-7786.MCR-17-0468. Epub 2017 Nov 13.  PMID:  29133594

Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.
Oladapo HO, Tarpley M, Sauer SJ, Addo KA, Ingram SM, Strepay D, Ehe BK, Chdid L, Trinkler M, Roques JR, Darr DB, Fleming JM, Devi GR, Williams KP.
Cancer Lett. 2017 Dec 28;411:136-149. doi: 10.1016/j.canlet.2017.09.033. Epub 2017 Sep 28.  PMID:  28965853

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, Strum JC.
Oncotarget. 2017 Jun 27;8(26):42343-42358. doi: 10.18632/oncotarget.16216.
PMID: 28418845

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL.
Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20.
PMID:  28108460

A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo.
Crowe LB, Hughes PF, Alcorta DA, Osada T, Smith AP, Totzke J, Loiselle DR, Lutz ID, Gargesha M, Roy D, Roques J, Darr D, Lyerly HK, Spector NL, Haystead TAJ.
ACS Chem Biol. 2017 Apr 21;12(4):1047-1055. doi: 10.1021/acschembio.7b00006. Epub 2017 Feb 23. PMID:  28103010

Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer.
Bowerman CJ, Byrne JD, Chu KS, Schorzman AN, Keeler AW, Sherwood CA, Perry JL, Luft JC, Darr DB, Deal AM, Napier ME, Zamboni WC, Sharpless NE, Perou CM, DeSimone JM.
Nano Lett. 2017 Jan 11;17(1):242-248. doi: 10.1021/acs.nanolett.6b03971. Epub 2016 Dec 22.
PMID:  27966988

Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer.
Alwarawrah Y, Hughes P, Loiselle D, Carlson DA, Darr DB, Jordan JL, Xiong J, Hunter LM, Dubois LG, Thompson JW, Kulkarni MM, Ratcliff AN, Kwiek JJ, Haystead TA.
Cell Chem Biol. 2016 Jun 23;23(6):678-88. doi: 10.1016/j.chembiol.2016.04.011. Epub 2016 Jun 2. PMID:  27265747

An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu JY, Paulk J, Xiong J, Clark KS, Fedoriw Y, Qi J, Burd CE, Bradner JE, Sharpless NE.
Nat Med. 2016 Jun;22(6):632-40. doi: 10.1038/nm.4092. Epub 2016 May 2.
PMID:  27135738

cMET inhibitor crizotinib impairs angiogenesis and reduces tumor burden in the C3(1)-Tag model of basal-like breast cancer.
Cozzo AJ, Sundaram S, Zattra O, Qin Y, Freemerman AJ, Essaid L, Darr DB, Montgomery SA, McNaughton KK, Ezzell JA, Galanko JA, Troester MA, Makowski L.
Springerplus. 2016 Mar 19;5:348. doi: 10.1186/s40064-016-1920-3. eCollection 2016.
PMID:  27057482

Weight loss reduces basal-like breast cancer through kinome reprogramming.
Qin Y, Sundaram S, Essaid L, Chen X, Miller SM, Yan F, Darr DB, Galanko JA, Montgomery SA, Major MB, Johnson GL, Troester MA, Makowski L.
Cancer Cell Int. 2016 Apr 1;16:26. doi: 10.1186/s12935-016-0300-y. eCollection 2016.
PMID:  27042159

Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.
Usary J, Darr DB, Pfefferle AD, Perou CM.
Curr Protoc Pharmacol. 2016 Mar 18;72:14.38.1-11. doi: 10.1002/0471141755.ph1438s72. Review.
PMID:  26995547

IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.
Carson CC, Moschos SJ, Edmiston SN, Darr DB, Nikolaishvili-Feinberg N, Groben PA, Zhou X, Kuan PF, Pandey S, Chan KT, Jordan JL, Hao H, Frank JS, Hopkinson DA, Gibbs DC, Alldredge VD, Parrish E, Hanna SC, Berkowitz P, Rubenstein DS, Miller CR, Bear JE, Ollila DW, Sharpless NE, Conway K, Thomas NE.
Clin Cancer Res. 2015 May 1;21(9):2167-76. doi: 10.1158/1078-0432.CCR-14-1826.
PMID:  25934889

Quantification of Microvascular Tortuosity during Tumor Evolution Using Acoustic Angiography.
Shelton SE, Lee YZ, Lee M, Cherin E, Foster FS, Aylward SR, Dayton PA.
Ultrasound Med Biol. 2015 Jul;41(7):1896-904. doi: 10.1016/j.ultrasmedbio.2015.02.012. Epub 2015 Apr 7.
PMID:  25858001

Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O’Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK.
Mol Cancer Ther. 2015 Apr;14(4):920-30. doi: 10.1158/1535-7163.MCT-14-0474.
PMID:  25824335

Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation.
He Z, Schulz A, Wan X, Seitz J, Bludau H, Alakhova DY, Darr DB, Perou CM, Jordan R, Ojima I, Kabanov AV, Luxenhofer R.
J Control Release. 2015 Jun 28;208:67-75. doi: 10.1016/j.jconrel.2015.02.024. Epub 2015 Feb 26. PMID:  25725361

Local iontophoretic administration of cytotoxic therapies to solid tumors.
Byrne JD, Jajja MR, O’Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM.
Sci Transl Med. 2015 Feb 4;7(273):273ra14. doi: 10.1126/scitranslmed.3009951.
PMID:  25653220

Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Chandler RL, Damrauer JS, Raab JR, Schisler JC, Wilkerson MD, Didion JP, Starmer J, Serber D, Yee D, Xiong J, Darr DB, Pardo-Manuel de Villena F, Kim WY, Magnuson T.
Nat Commun. 2015 Jan 27;6:6118. doi: 10.1038/ncomms7118.
PMID:  25625625

Circadian clock, cancer, and chemotherapy.
Sancar A, Lindsey-Boltz LA, Gaddameedhi S, Selby CP, Ye R, Chiou YY, Kemp MG, Hu J, Lee JH, Ozturk N.
Biochemistry. 2015 Jan 20;54(2):110-23. doi: 10.1021/bi5007354. Epub 2014 Oct 29.
PMID:  25302769

Loss of p16Ink4a With Retention of p19Arf Predisposes Mice to Tumorigenesis
Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW and DePinho RA . (2001). Nature, 413, 86–91
PMID: 11544531